Table 5. Summary of therapeutic responses criteria at week 24.
| Clinical end point | Treatment groups | |||||
|---|---|---|---|---|---|---|
| I (n=20) | GT (n=20) | EX (n=20) | I+GT (n=20) | I+EX (n=20) | GT+EX (n=20) | |
| ACR20 n (%) | 10 (50%) | 5 (25%) | 8 (40%) | 2 (10%) | 10 (50%) | 2 (10%) |
| ACR50 n (%) | 7 (35%) | 6 (30%) | 9 (45%) | 7 (35%) | 2 (10%) | 6 (30%) |
| ACR70 n (%) | 3 (15%) | 9 (45%) | 3 (15%) | 11 (55%) | 8 (40%) | 12 (60%) |
| EULAR response score | ||||||
| Good (>1.2%): | 9 (45%) | 10 (50%) | 9 (45%) | 11 (55%) | 12 (60%) | 15 (75%) |
| Moderate (0.6 to −1.2%) | 5 (25%) | 9 (45%) | 5 (25%) | 8 (44%) | 3 (15%) | 4 (20%) |
| No response (>0.6%) | 6 (30%) | 1 (5%) | 6 (30%) | 1 (5%) | 5 (25%) | 1 (5%) |
ACR20: American College of Rheumatology 20% improvement; ACR50: American College of Rheumatology 50% improvement; ACR70: American College of Rheumatology 70% improvement. I: infliximab group; GT: green tea group; EX: exercise group; I + GT: infliximab + green tea; I + EX: infliximab + exercise group; GT + EX: green tea + exercise group; EULAR: European League Against Rheumatism